Table 1

Clinical features and gene promoter hypermethylation in primary tumors and serum in head and neck cancer patients

Primary tumorsaSerum
p16+p16−MGMT+MGMT−DAP-Kb+DAP-K−+
Patientsc2360265715642129
Stage
I–II416 P = NSd713 P = NS019 P = 0.01636 P = NS
III–IV1944194415451720
Node involvement
N0622 P = NS820 P = NS127 P = 0.01457 P = NS
N+1738163714371519
Tumor size
T1–2626 P = NS1020 P =NS426 P = NS88 P = NS
T3–41734163711381218
Tumor locatione
OC143612367391018
L41151221145
HP18362933
OP33 P = NS51 P =0.01842 P = 0.0232 P = NS
PS12120311
  • a +/−, presence of absence of gene promoter hypermethylation for any of the three genes.

  • b DAP-K, DAP-kinase.

  • c Patients with available clinical data. The patients with recurrent disease at the moment of the first visit are not included in the table.

  • d P = NS represents P > 0.05.

  • e OC, Oral cavity; L, Larynx; HP, Hypopharynx; OP, Oropharynx; PS, Perinasal sinus.